新冠疫情期间美国类风湿关节炎患者改善病情抗风湿药治疗变化:三个月观察性研究
本研究基于FORWARD登记库,调查2020年3月至5月美国新冠疫情初期类风湿关节炎(RA)患者的用药、生活方式与临床照护变化。734名受访者中221人(30%)报告用药变化;疫情前使用糖皮质激素是用药变化的最强预测因素(OR 3.0,95%CI 1.9–4.9)。2020年4月ACR指南发布后,患者自行调整用药的比例下降,医生指导下的调整增多。
要点
- 30%的RA受访者在疫情头三个月内报告了用药变化。
- 疫情前使用糖皮质激素是用药变化的最强预测因素(OR 3.0)。
- ACR指南发布后医生指导的用药调整比例上升。
核心结论
- 美国RA患者在新冠疫情头三个月内普遍调整了DMARD治疗,疫情前使用糖皮质激素是调整用药的强预测因素,ACR指南发布后用药变化更多由医生指导。
研究设计与样本
- 基于FORWARD(美国国家风湿病数据库)观察性登记库,纳入2020年5月完成新冠网络问卷调查、且此前已有基线和疫情前用药数据的成年RA患者,共734人;采用校正年龄、性别、合并症、教育、保险、疾病活动度、疲劳及多症状困扰的logistic模型比较不同DMARD暴露下的用药变化。
主要发现
- 734名受访者中221人(30%)报告用药变化;用药变化者中糖皮质激素使用比例高于未变化者(33%对18%)。
- 用药变化者疫情前使用非羟氯喹传统DMARD的比例低于未变化者(49%对62%),疫情期间经历经济困难的比例更高(23%对15%)。
- JAK抑制剂使用与用药变化相关(OR 1.9,95%CI 1.0–3.4),但多变量模型中仅疫情前使用糖皮质激素仍为强预测因素(OR 3.0,95%CI 1.9–4.9)。
- 照护方式变化与肺疾病(OR 2.9,95%CI 1.3–6.5)、更差的RA疾病活动度(OR 1.1,95%CI 1.0–1.1)及糖皮质激素使用(OR 1.6,95%CI 1.0–2.5)显著相关。
- ACR指南2020年4月发布前后用药变化发生率相同,但自行调整用药在指南发布前约为发布后的两倍,医生指导的调整在发布后更常见。
关键数值与推荐
- 用药变化定义为受访者自报的用药改变;糖皮质激素、非羟氯喹传统DMARD、JAK抑制剂按疫情前暴露分类。
- 多变量logistic模型校正年龄、性别、肺及心血管疾病等合并症、教育水平、保险状态、RA疾病活动度、疲劳和多症状困扰。
- ACR于2020年4月首次发布新冠疫情期间成人风湿病管理指南,研究据此比较发布前后的用药变化。
临床怎么用
- 疫情期间应关注RA患者尤其是疫情前使用糖皮质激素者的用药调整需求,并加强医生指导以减少患者自行停药或改药。
- 对合并肺疾病、疾病活动度较高或使用糖皮质激素的RA患者,应关注其照护方式变化并主动随访。
局限性
- 为观察性登记库研究,用药变化为患者自报,可能存在回忆偏倚。
- 样本来自自愿参与FORWARD登记库的RA患者,结果外推需谨慎。
- 观察期仅为疫情头三个月,未评估用药变化对RA结局的长期影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To understand medication, lifestyle, and clinical care changes of persons with rheumatoid arthritis (RA) during the first months (March 2020 through May 2020) of the COVID-19 pandemic in the US. METHODS: Data were collected from adults with RA participating in FORWARD, The National Databank for Rheumatic Diseases observational registry, who answered COVID-19 web-based surveys in May 2020 and previously provided baseline characteristics and medication use prior to the US COVID-19 pandemic. We compared medication changes by disease-modifying antirheumatic drug (DMARD) exposure in logistic models that were adjusted for age, sex, comorbidities including pulmonary and cardiovascular diseases, education level, health insurance status, RA disease activity, fatigue, and polysymptomatic distress. RESULTS: Of 734 respondents, 221 (30%) reported medication changes. Among respondents who experienced a medication change, i.e., "medication changers/changers," glucocorticoids (GCs) were more commonly used compared to respondents who did not experience a medication change ("non-changers") (33% versus 18%). Non-hydroxychloroquine conventional DMARDs were less commonly used in changers compared to non-changers pre-COVID-19 (49% versus 62%), and changers reported more economic hardship during the COVID-19 pandemic compared to non-changers (23% versus 15%). While JAK inhibitor use was associated with the likelihood of a medication change, with an odds ratio (OR) of 1.9 (95% confidence interval [95% CI] 1.0, 3.4), only pre-COVID GC use remained a strong predictor for medication change in multivariable models (OR 3.0 [95% CI 1.9, 4.9]). Change in care was observed to have a significant association with pulmonary disease (OR 2.9 [95% CI 1.3, 6.5]), worse RA disease activity (OR 1.1 [95% CI 1.0, 1.1]), and GC use (OR 1.6 [95% CI 1.0, 2.5]). While the incidence of medication changes was the same before and after the American College of Rheumatology (ACR) guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic were first published in April 2020, self-imposed changes in medication were approximately twice as likely before publication of the guidelines, and physician-guided changes were more likely after publication. CONCLUSION: Persons with RA in the US made substantial medication changes during the first three months of the COVID-19 pandemic, and changes among persons with RA after publication of the ACR guidance in April 2020 were made with increased physician guidance.
引用
- Michaud K, Pedro S, Wipfler K, et al. Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study. Arthritis Care Res (Hoboken). 2021. PMID: 33787086. doi:10.1002/acr.24611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。